NBOMe-2C-D
Sign in to saveAlso known as 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
25D-NBOMe, also known as NBOMe-2C-D and "divination", is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.
~4 min read
Encyclopedic overview
20 sectionsContents
- Use and effects
- Toxicity and harm potential
- Neurotoxic and cardiotoxic actions
- Emergency treatment
- Interactions
- Pharmacology
- Pharmacodynamics
- History
- Society and culture
- Legal status
- Canada
- China
- Finland
- Sweden
- United Kingdom
- United States
- See also
- Notes
- References
- External links
25D-NBOMe, also known as NBOMe-2C-D and "divination", is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.
==Use and effects== The dose range of 25D-NBOMe has been given as 0.3 to 1.2mg or more sublingually, with a typical dose estimate of 1.0mg.
Excerpted from Wikipedia’s “NBOMe-2C-D” article, available under the CC BY-SA 4.0 licence.